Nucleotide analogues having the general formula (I) and pharmaceutically acceptable derivatives: ##STR1## wherein n is 0 or an integer; X is O or S, CH.sub.2, CH-halogen, CH--N.sub.3, or C.dbd.CH.sub.2 ; Q and U are independently selected from: O, S, and CH(R.sub.a) wherein R.sub.a is hydrogen, OH, halogen, N.sub.3, NH.sub.2, SH, carboxyl, C.sub.1-6 alkyl or R.sub.a is CH.sub.2 (R.sub.b) wherein R.sub.b is hydrogen, OH, SH, NH.sub.2, C.sub.1-6 alkyl or carboxyl; or both Q and U are CH when Q and U are linked by a double bond; Z is selected from: O, a C.sub.1-6 alkoxy, a C.sub.1-6 thioalkyl, a C.sub.1-6 aminoalkyl, (CH.sub.2).sub.m wherein m is 0 or an integer, and N(R.sub.c).sub.2 wherein both R.sub.c are independently hydrogen or a C.sub.1-6 alkyl; and R2 is a purine or pyrimidine base or an analogue or derivative thereof. Members of this series of analogues possess anti-viral activity.
This is a division of application Ser. No. 08/465,921, filed Jun. 6, 1995, now abandoned which is a division of application Ser. No. 08/171,527 filed Dec. 22, 1993 now abandoned entitled ANTIVIRAL COMPOUNDS.
Disclosed are novel prodrugs represented by the following structural formula: ##STR1## Z is oxygen or sulfur; Y is, together with a hydroxy group, acyclovir or an analog of acyclovir; A is a substituted benzyl group with one or more protected hydroxy or protected amine groups in the ortho or para positions, relative to the phosphate ester, which can be converted in vivo to a hydroxy or amino group. Also disclosed is a method of treating a viral infection in an individual or animal. The method comprises administering to the individual or animal a therapeutically effective amount of a prodrug represented by structural formula shown above.
The present invention relates to benzimidazole derivatives and their use in medical therapy particularly for the treatment or prophylaxis of restenosis.
Viral infections selected from the group consisting of herpes simplex virus, varicella zoster virus, respiratory syncytial virus and cytomegalovirus can be treated by administering to the host a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof; ##STR1## wherein Y, Ra, and R1 are as defined herein. The compounds and salts can also be used to inhibit viral replication of these viruses in cells.
Compounds of formula I: ##STR1## wherein Y, X, R1 and Ra are defined herein are in methods for treating or preventing a viral infections selected from herpes simplex virus, varicella zoster virus, respiratory syncytial virus and cytomegalovirus infections.
In accordance with the present invention there is provided a method for treating or preventing a Flaviviridea viral infection in a host comprising administering a therapeutically effective amount of at least one compound of formula (I) or (II) ##STR1## or a pharmaceutically acceptable salts thereof, wherein Ra, R, Z and Y are defined in the application.
